Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review
Supportive Care in Cancer · 2025-10 · 33 (10)
DOI: 10.1007/s00520-025-09952-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Supportive Care in Cancer, online erschienen am 07.10.2025. Verfasst von Maria T Cruz Carreras und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mcruz3@mdanderson.org. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Hematologic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1 have transformed cancer therapy but may trigger rare, sometimes fatal hematologic immune-related adverse events (irAEs). The most frequent hematologic irAEs are anemia, thrombocytopenia, and pancytopenia, which occur more often with CTLA-4 inhibitors and in patients receiving combination therapy. Risk is heightened when ICIs are combined with chemotherapy or radiation. Common symptoms include fatigue, abnormal bleeding, easy bruising, and recurrent infections. Diagnosis relies on laboratory studies, histologic evaluation, and review of medication history. Management typically involves ICI discontinuation and immunosuppression with corticosteroids or rituximab; adjunctive options include IVIG, transfusions, or plasmapheresis depending on severity. Research is also exploring cytokines such as IL-2, IL-7, and IL-15 for ICI-related lymphopenia. Current evidence is drawn mainly from case reports and small series, highlighting the need for larger studies to clarify incidence, mechanisms, and optimal management. Recent pharmacovigilance and outcomes data confirm these events remain rare and can present late, underscoring the need for long-term surveillance and robust monitoring systems [Fletcher K and Johnson DB 2024; Durbin SM et al. 2025; Yang Y. et al. 2024; Han X. et al. 2025].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mcruz3@mdanderson.org.
- Department of Medicine, Ponce Health Sciences University, Ponce, PR, USA.
- Department of Medicine, Universidad Anáhuac, Querétaro, México.
- Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zitieren
APA
Cruz Carreras, M. T., González Landrón, F., López, N., Padrón Alcántara, L., Markides, D. M., Burk, K. J., & Chaftari, P. (2025). Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review. Supportive Care in Cancer, 33(10). https://doi.org/10.1007/s00520-025-09952-2
Vancouver
Cruz Carreras MT, González Landrón F, López N, Padrón Alcántara L, Markides DM, Burk KJ, et al. Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review. Supportive Care in Cancer. 2025;33(10). doi:10.1007/s00520-025-09952-2
BibTeX
@article{CruzCarreras2025,
author = {Cruz Carreras, Maria T and González Landrón, Francisco and López, Natalie and Padrón Alcántara, Leticia and Markides, Dana M and Burk, Kathryn J and Chaftari, Patrick},
title = {Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review},
journal = {Supportive Care in Cancer},
year = {2025},
volume = {33},
number = {10},
doi = {10.1007/s00520-025-09952-2}
}
EUVIMED